Date: 2016-03-17
Type of information: Nomination
Compound:
Company: Transgene (France)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 17, 2016, Transgene announced the appointment of two new executives to its leadership team. Maud Brandely, MD, PhD joins Transgene from Pierre Fabre Oncologie, where she most recently served as Director of Clinical Development. John Felitti, JD, LLM joins from Sanofi, where he was Associate Vice President, Corporate Law, Finance and Securities Law. Both bring many years of industry and leadership experience to their positions. Dr. Brandely and Mr. Felitti will be members of Transgene’s Executive Committee and both will report to Mr. Archinard. In her position as Director of Clinical Development at Pierre Fabre Oncologie, Dr. Brandely oversaw all clinical trials (Phase I-Phase III) for the company’s cancer programs. She played a key role in the successful registration of Navelbine® oral (vinorelbine) for the treatment of both breast cancer and non-small cell lung cancer and for vinflunine in transitional cell carcinoma of the urothelial tract. Prior to Pierre Fabre, she was Director of Taxotere® Clinical Development at Rhone-Poulenc (now Sanofi), where she was responsible for global registration trials for that product. Dr. Brandely is an MD and has a PhD in immunology from the University of Paris VI. At Sanofi, Mr. Felitti oversaw legal matters including corporate governance, capital markets, finance, securities litigation and company law. He also headed legal support for a number of major strategic projects, including Sanofi’s successful bid for Genzyme. Prior to Sanofi, Mr. Felitti was an attorney at the leading international law firm, Shearman & Sterling. He is admitted to practice in New York and is a former member of the Paris Bar. In addition to his legal training at the University of Michigan and the University of Paris II (Panthéon), he holds degrees in economics from Harvard University and the College of Europe as well as a global executive MBA from INSEAD.
Financial terms:
Latest news:
